HC Wainwright Finds ‘Synergies In Treatment’ For This Bipolar-Focused Stock
HC Wainwright initiated coverage on NRx Pharmaceuticals Inc (NASDAQ:NRXP) with a Buying rating and a price target of $2. Earlier today, the FDA…
HC Wainwright Sees Over 300% Upside In This Cancer-Focused Stock
HC Wainwright has initiated Theseus Pharmaceuticals Inc (NASDAQ:THRX) with a Buy rating and a price target of $22 (310% upside). The analysts see…
Raymond James Thinks Haemonetics Growth Is ‘Underappreciated’
Earlier this week, Raymond James attended Haemonetics Corp’s (NYSE:HAE) Investor Day, where the management team presented a new Long-Range Plan (LRP), including…
This Biopharmaceutical Company Has A Better 1-Year Return Than Tesla, Apple, Starbucks, Nvidia And Microsoft
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) creates new possibilities via medicine to cure diseases and improve people's lives, and over the past year, marked gains in investors’ portfolios.
Takeda’s Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022.
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
Here's a roundup of top developments in the biotech space over the last 24 hours:
Endo Posts Disappointing Data From Frozen Shoulder Trial
Endo International plc (NASDAQ:ENDP) has announced topline results from its Phase 2 study of collagenase clostridium histolyticum (CCH) in participants with…
Oxford Biomedica Inks New Three Year Deal To Make AstraZeneca’s COVID-19 Vaccine
Oxford Biomedica plc (OTC:OXBDF) signed a new three-year agreement to potentially make AstraZeneca Plc’s (NASDAQ:AZN) COVID-19 vaccine beyond 2022. The new agreement represents…